Relax, Celgene investors. The situation isn't as bad as you think: analyst

celgene
Celgene's shares are well below where they should be in terms of price, Leerink Partners' Geoffrey Porges contends. (Celgene)

Celgene’s stock has taken a beating in recent months, thanks to a string of bad news. But the company’s situation isn’t quite as dire as its share price indicates, one analyst insists.

Leerink Partners analyst Geoffrey Porges broke things down to determine that if the worst-case scenario for the big biotech played out—as in, aging megablockbuster Revlimid doesn't record a cent in sales after 2022, and neither of two closely watched pipeline candidates, ozanimod and luspatercept, make it to market—“the stock would be trading at or around its current level,” he wrote to clients.

The way he sees it, Celgene’s portfolio and pipeline account for $89 per share with those three drugs blacked out. Celgene shares sat at just over $90 late Thursday morning.

Webinar This Week

OTC Innovation to Avoid Stagnation: Survey Insights, Expert Advice, and Latest Technologies to Boost Your Product’s Performance

Join us for a complimentary webinar on November 13 at 11am ET / 8am PT. Listen to industry experts as they analyze the critical role of innovation in OTC products, and strategies for achieving it.

Thing is, that worst-case scenario isn’t what he thinks Celgene will wind up facing. The possibility that both ozanimod and luspatercept strike out before winning FDA approval “seems highly unlikely based on the available data,” he wrote.

RELATED: Celgene slips as FDA refuses to review critical multiple sclerosis drug ozanimod

That’s not to say green lights for the prospects are gimmes, though. In February, the FDA refused to review Celgene’s approval application for ozanimod, concluding that the company hadn’t provided the necessary preclinical and clinical pharmacology information on the multiple sclerosis wannabe.

Meanwhile, though, Porges’ bast-case scenario—which “includes a slow revenue decline for Revlimid post-2022 and ozanimod’s approval in MS during 2019 with a 50% probability of success in all indications”—results in “a net present value of $140/share,” he wrote.

RELATED: Celgene's Revlimid fails lymphoma trial, and it's more than a data shortfall: analyst

Porges, for his part, isn’t surprised by the share-price disparity, considering “the company’s recent missteps and misjudgments,” including a doomed Revlimid trial, he wrote. But it does go to show that Celgene’s stock boasts “remarkable upside” for those investors “willing to step in at the current ‘distressed’ valuation.”

Suggested Articles

Intercept presented a data analysis that found treatment with Ocaliva led to "early and consistent improvements" in a range of noninvasive tests.

Days before Amarin faces a pivotal FDA vote on its Vascepa expansion, advisors are set to scrutinize the placebo used in its pivotal outcomes trial.

Both IL-17A inhibitors have rolled out data showing they work in non-radiographic axial spondyloarthritis.